Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 8/20 | 0.46 |
| ▸ | NOS1 | P29475 | 8/20 | 0.46 |
| ▸ | NOS2 | P35228 | 8/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7083835 | 0.84 | NOS3 (0.47) | NOS3NOS1NOS2 | |
| Dimethylamine SCHEMBL5833808 | 0.82 | NOS3 (0.42) | NOS3NOS1NOS2 | |
| SCHEMBL5833998 | 0.80 | NOS3 (0.42) | NOS3NOS1NOS2 | |
| SCHEMBL5833096 | 0.79 | NOS1 (0.72) | NOS3NOS1NOS2KDM4ESMN1; SMN2 | |
| SCHEMBL5833902 | 0.79 | NOS3 (0.41) | NOS3NOS1NOS2KDM4E | |
| SCHEMBL5833970 | 0.79 | NOS3 (0.39) | NOS3NOS1NOS2KDM4ESMN1; SMN2 | |
| SCHEMBL7086015 | 0.78 | NOS3 (0.51) | NOS3NOS1NOS2KDM4ESMN1; SMN2 | |
| SCHEMBL7086013 | 0.77 | NOS3 (0.49) | NOS3NOS1NOS2KDM4ESMN1; SMN2 | |
| SCHEMBL5833799 | 0.76 | NOS3 (0.40) | NOS3NOS1NOS2 | |
| SCHEMBL5833168 | 0.74 | NOS3 (0.32) | NOS3NOS1NOS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1155000-B1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS | PFIZER PROD INC (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6372768-B2 | NERVOUS SYSTEM DISORDERS | PFIZER INC | 2002-04-16 | — | — | US | disclosed |
| US-20010014689-A1 | 2-aminopyridines containing fused ring substituents | LOWE JOHN A (US) | 2001-08-16 | — | — | US | disclosed |
| US-6211208-B1 | INHIBITION OF NITRIC OXIDE SYNTHETASE, ANTIINFLAMMATORY AGENTS | PFIZER INC | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014689-A1 | 2-aminopyridines containing fused ring substituents | CBR1, CBR3, NOS2 | NOS3 4/4885NOS1 5/4885NOS2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.